Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT. Gelfand JM, et al. Among authors: syed mn. J Am Acad Dermatol. 2020 Dec;83(6):1704-1716. doi: 10.1016/j.jaad.2020.09.001. Epub 2020 Sep 4. J Am Acad Dermatol. 2020. PMID: 32891785 Free PMC article.
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM. Syed MN, et al. J Am Acad Dermatol. 2020 Nov;83(5):1523-1526. doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2. J Am Acad Dermatol. 2020. PMID: 32622891 Free PMC article. No abstract available.
Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic.
Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM. Syed MN, et al. J Am Acad Dermatol. 2021 Jan;84(1):161-163. doi: 10.1016/j.jaad.2020.08.095. Epub 2020 Aug 26. J Am Acad Dermatol. 2021. PMID: 32860913 Free PMC article. No abstract available.
Commentary.
Shin DB, Syed MN, Gelfand JM. Shin DB, et al. Among authors: syed mn. J Am Acad Dermatol. 2021 Mar;84(3):e161-e162. doi: 10.1016/j.jaad.2020.10.001. Epub 2020 Oct 8. J Am Acad Dermatol. 2021. PMID: 33039482 Free PMC article. No abstract available.
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. Gelfand JM, et al. Among authors: syed mn. J Am Acad Dermatol. 2021 May;84(5):1254-1268. doi: 10.1016/j.jaad.2020.12.058. Epub 2021 Jan 7. J Am Acad Dermatol. 2021. PMID: 33422626 Free PMC article.
Response to: "Methotrexate Use and Liver Outcomes in Psoriasis and Rheumatoid Arthritis Patients: A Commentary on 'Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study'".
Gelfand JM, Syed MN. Gelfand JM, et al. Among authors: syed mn. J Am Acad Dermatol. 2021 Dec;85(6):e401. doi: 10.1016/j.jaad.2021.07.068. Epub 2021 Aug 14. J Am Acad Dermatol. 2021. PMID: 34403717 No abstract available.
36 results